Bipolar Disorder and Diabetes Mellitus

Year 2010, Volume: 2 Issue: 1, 66 - 74, 01.03.2010

Sermin Kesebir A. Görkem Gençer

Abstract

Comorbid endocrine and cardiovascular situations with bipolar disorder usually result from the bipolar disorder itself or as a consequence of its treatment. With habits and lifestyle, genetic tendency and side effects, this situation is becoming more striking. Subpopulations of bipolar disorders patients should be considered at high risk for diabetes mellitus. The prevalence of diabetes mellitus in bipolar disorder may be three times greater than in the general population. Comorbidity of diabetes causes a pathophysiological overlapping in the neurobiological webs of bipolar cases. Signal mechanisms of glycocorticoid/insulin and immunoinflammatory effector systems are junction points that point out the pathophysiology between bipolar disorder and general medical cases susceptible to stress. Glycogen synthetase kinase (GSK-3) is a serine/treonine kinase and inhibits the transport of glucose stimulated by insulin. It is affected in diabetes, cancer, inflammation, Alzheimer disease and bipolar disorder. Hypoglycemic effect of lithium occurs via inhibiting glycogen synthetase kinase. When comorbid with diabetes, the other disease -for example bipolar disorder, especially during its acute manic episodes-, causes a serious situation that presents its influences for a lifetime. Choosing pharmacological treatment and treatment adherence are another important interrelated areas. The aim of this article is to discuss and review the etiological, clinical and therapeutic properties of diabetes mellitus and bipolar disorder comorbidity.

Keywords

Bipolar Disorder, Diabetes Mellitus , Late Onset, Comorbidity

Bipolar Bozukluk ve Diyabetes Mellitus

Abstract

Bipolar bozukluk tanısı alan hastalarda görülen endokrin ve kardiyovasküler durumlar bipolar bozukluğun kendinden ya da sağaltımından kaynaklanmaktadır. Alışkanlıklar, yaşam tarzı, genetik yatkınlık ve tedavi yan etkileri ile bu tablolar kimi zaman giderek ağırlaşır. Bipolar bozukluğu olan olguların bir alt grubu diyabet geliştirmeye yatkındır. Öte yandan, bipolar olgular arasında diyabet sıklığı genel popülasyondakinden üç kat daha fazladır. Diyabetes mellitus eştanısı bipolar bozukluğu olan olguların nörobiyolojik ağlarında patofizyolojik olarak bir üst üste binişiklik yaratmaktadır. Glukokortikoid/insülin sinyal mekanizmaları ve immünoinflamatuar efektör sistemler bipolar bozukluk ile stres duyarlı genel tıbbi durumlar arasındaki patofizyolojiye işaret eden kesişim noktalarıdır. Glikojen sentetaz kinaz (GSK-3) bir serin/treonin kinaz olup insülinin uyardığı glukoz taşınımını baskılamaktadır. Bu enzim, diyabetes mellitus, kanser, inflamasyon, Alzheimer hastalığı ve bipolar bozuklukta etkilenir. Örneğin; bipolar bozukluk tedavisinde kullanılan lityum hipoglisemik etkisini GSK-3'ü inhibe ederek gösterir. Öte yandan, diyabetes mellitus birlikte bulunduğu diğer hastalığın -örneğin bipolar bozukluk, özellikle akut manik dönemleri- sürecini yaşam boyu etkileyen önemli bir durumdur. Tedavi seçimi ve tedavi uyumu ise bu iki hastalık arasında bir diğer önemli etkileşim alanıdır. Bu yazının amacı diyabetes mellitus ve bipolar bozukluk birlikteliğini etiyolojik, klinik ve tedavi özellikleri yönünden tartışmak ve gözden geçirmektir.

Keywords

Bipolar Bozukluk, Diyabetes Mellitus, Geç Başlangıç, Komorbidite

References

• Fagiolini A. Medical monitoring in patients with bipolar disorder: a review of data. J Clin Psychiatry 2008; 69:16-18.
• Ruzickova M, Slaney C, Garnham J, Alda M. Clinical features of bipolar disorder with and without comorbid diabetes mellitus. Can J Psychiatry 2003; 48:458-461.
• Evans DL, Charney DS, Lewis L, Golden RN, Gorman JM, Krishnan KR et al. Mood disorders in the medically ill: scientific review and recommendations. Biol Psychiatry 2005; 158:175-189.
• Fagiolini A., Goracci A. The effects of undertreated chronic medical illnesses in patients with severe mental disorders. J Clin Psychiatry 2009; 70:22-29.
• McIntyre RS, Konarski JZ, Misener VL, Kennedy SH. Bipolar disorder and diabetes mellitus: epidemiology, etiology, and treatment implications. Ann Clin Psychiatry 2005; 17:83-93.
• Van Winkel R, De Hert M, Van Eyck D, Hanssens L, Wampers M, Scheen A et al. Prevalence of diabetes and the metabolic syndrome in a sample of patients with bipolar disorder. Bipolar Disord 2008; 10: 342-348.
• McIntyre RS, Nguyen HT, Soczynska JK, Lourenco MT, Woldeyohannes HO, Konarski JZ. Medical and substance-related comorbidity in bipolar disorder: translational research and treatment opportunities. Dialogues Clin Neurosci 2008; 10:203-213.
• Castilla-Puentes R. Effects of psychotropics on glycosylated hemoglobin (HbA1c) in a cohort of bipolar patients. Bipolar Disord 2007; 9:772-778.
• Levitt KLE, Swami SA, Murphy M, Murphy KM, Jawad AF, McKnight-Menci H et al. Neuropsychiatric disorders at the presentation of type 2 diabetes mellitus in children. Pediatr Diabetes 2005; 6:84-89.
• Glasner H. [Diseases of the central nervous system in diabetes mellitus]. Fortschr Med 1977; 95:931-935.
• Rayasam GV, Tulasi VK, Sodhi R, Davis JA, Ray A. Glycogen synthase kinase 3: more than a namesake. Br J Pharmacol 2009; 156:885-898.
• Patel DS, Dessalew N, Igbal P, Bharatam PV. Structure-based approaches in thr design of GSK-3 selective inhibitors. Curr Protein Pept Sci 2007; 8:352-364.
• Torres RE, Leroy XH, Katrivanou A, Katrivanou A, Gourzis P, Papachatzopoulou A et al. Mutation screening of the Wolfram syndrome gene in psychiatric patients. Mol Psychiatry 2001; 6:39-43.
• Kavamato T, Horikawa Y, Tanaka T, Kabe N, Takeda J, Mikuni M. Genetic variations in the WFS1 gene in Japanese with type 2 diabetes and bipolar disorder. Mol Genet Metab 2004; 82:238-245.
• Serretti A, Cusin C, Lorenzi C, Lorenzi C, Lilli R, Lattuada E et al. Multicentre Italian family-based association study on tyrosine hydroxylase, catechol-O-methyl transferase and Wolfram syndrome 1 polymorphisms in mood disorders. Psychiatr Genet 2003; 13:121-126.
• Newman JC, Holden RJ. The 'cerebral diabetes' paradigm for unipolar depression. Med Hypotheses 1993; 41:391-408.
• Kato T. [Mitochondrial dysfunction in bipolar disorder]. Nihon Shinkei Seishin Yakurigaku Zasshi 2005; 25:61-72.
• Regenold WT, Kling AM, Hauser P. Elevated sorbitol concentration in the cerebrospinal fluid of patients with mood disorders. Psychoneuroendocrinology 2000; 25:593-606.
• Regenold WT, Hisley KC, Phatak P, Marano CM, Obuchowski A, Lefkowitz DM et al. Relationship of cerebrospinal fluid glucose metabolites to MRI deep white matter hyperintensities and treatment resistance in bipolar disorder patients. Bipolar Disord 2008; 10:753-764.
• Oulis P, Karapoulios E, Kouzoupis V, Masdrakis VG, Kontoangelos KA, Makrilakis K et al. Oxcarbazepine as monotherapy of acute mania in insufficiently controlled type-1 diabetes mellitus: a case-report. Ann Gen Psychiatry 2007; 6:25.
• Hajek T, Hahn M, Slaney C, Garnham J, Green J, Ruzickova M et al. Rapid cycling bipolar disorders in primary and tertiary care treated patients. Bipolar Disord 2008; 10:495-502.
• Langevin R, Langevin M, Curnoe S, Bain J. The prevalence of diabetes among sexual and violent offenders and its co-occurrence with cognitive impairment, mania, psychotic symptoms and aggressive behavior. Int J Prison Health 2008; 4:83-95.
• Vestergaard P, Schou M. Does long-term lithium treatment induce diabetes mellitus? Neuropsychobiology 1987; 17:130-132.
• Waziri R, Nelson J. Lithium in diabetes mellitus: a paradoxical response. J Clin Psychiatry 1978; 39:623-625.
• American Diabetes Association. Screening for type 2 diabetes. Diabetes Care 2004; 27 (Suppl 1):S11–S14.